Loading...
•
Sep 30, 2024
ResMed Q1 2025 Earnings Report
ResMed's Q1 2025 results reflected ongoing momentum and strong execution across the business.
Key Takeaways
ResMed reported an 11% increase in revenue, a 34% increase in operating profit, and a non-GAAP operating profit increase of 27%. The company's focus on operational excellence led to margin expansion. They are celebrating 35 years of growth and innovation, with a newly launched 2030 strategy to transform sleep health, breathing health, and healthcare technology at home.
Revenue increased by 11% to $1.2 billion.
Gross margin improved to 58.6%, with non-GAAP gross margin at 59.2%.
Income from operations increased by 34%.
Diluted earnings per share were $2.11, with non-GAAP diluted earnings per share at $2.20.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
ResMed held its 2024 Investor Day and unveiled ResMed’s 2030 strategy to drive growth, profitability, and shareholder returns. As part of Investor Day, ResMed announced five-year revenue and earnings growth outlook, supported by ResMed’s plans to accelerate product and technology innovation, operational excellence, commercial execution, and financial strength. ResMed’s updated ambition is to help more than 500 million people achieve their full health potential in 2030.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...